What Has Been The Evolution of the Viral Hepatitis Market in Recent Years?
The viral hepatitis market has seen considerable growth due to a variety of factors.
• In the past few years, the size of the viral hepatitis market has experienced consistent growth. The market, which is expected to rise from $16.21 billion in 2024 to $16.93 billion in 2025, will have a compound annual growth rate (CAGR) of 4.4%.
Factors such as vaccine development, blood screening programs, antiviral drugs, and global health initiatives have played a significant role in the growth witnessed during the historic period.
How Will the Viral Hepatitis Market?
The viral hepatitis market is expected to maintain its strong growth trajectory in upcoming years.
• The market for viral hepatitis is projected to witness consistent expansion in the ensuing years. Its value is anticipated to reach $19.97 billion by 2029, reflecting a compound annual growth rate (CAGR) of 4.2%.
The expected growth during the forecast period is primarily due to improved access to treatment, public health regulations, combination therapies, and health equity schemes. Key trends emerging in the forecast timeframe comprise tailored treatment strategies, digital healthcare instruments, AI utilization in disease tracking, and hepatitis C micro-elimination.
Which Factors Are Boosting Growth In The Viral Hepatitis Market?
The escalating incidence of hepatitis is predicted to drive the expansion of the viral hepatitis market. Hepatitis, an infection of the liver, can be triggered by a variety of infectious viruses and non-infectious substances leading to multiple health concerns. Viruses causing such a condition include Hepatitis A, B, C, D, and E, leading to inflammation and damage to the liver. For example, as per the European Centre for Disease Prevention and Control, a Sweden-based health agency, in April 2024, there were 28,855 recorded instances of hepatitis B virus infection across 30 EU/EEA Member States in 2022. This is a 78% increase from 16,187 cases in 2021. Furthermore, the case count in 2022, totaling 28,420, equates to a crude rate of 8.5 cases per 100,000 people. Hence, the escalating incidence of hepatitis will fuel the growth of the viral hepatitis market. The Viral Hepatitis Market is predicted to grow due to the surge in the amount of research and development activities in this field. The research and development aspect of viral hepatitis covers a wide spectrum of activities such as development of vaccines and antiviral medications, public health interventions, clinical trials, genomic research and epidemiological studies, among others. An uptick in these activities leads to treatment innovations, an increased range for diagnosis and prevention, an enhancement in global health initiatives, and increased competition amongst pharmaceuticals. As evidence, researchers in Melbourne, as per The Peter Doherty Institute for Infection and Immunity in Australia, procured $1.7 million in November 2022 for the forthcoming five years through the mRNA Victoria Activation Program to advance their groundbreaking work in finding a cure for hepatitis B virus infection. Consequently, the surge in the amount of research and development activities fuels the growth of the viral hepatitis market.
What Key Areas Define The Segmentation Of The Global Viral Hepatitis Market?
The viral hepatitis market covered in this report is segmented –
1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis
3) By Treatment: Antiviral Drugs, Surgery, Vaccine, Immune Modulator Drugs, Other Treatments
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Hepatitis A: Acute Hepatitis A, Chronic Hepatitis A
2) By Hepatitis B: Acute Hepatitis B, Chronic Hepatitis B, Hepatitis B Carrier
3) By Hepatitis C: Acute Hepatitis C, Chronic Hepatitis C
4) By Other Disease Types: Hepatitis D, Hepatitis E
Pre-Book The Viral Hepatitis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Viral Hepatitis Market?
Firms in the viral hepatitis market are making strides in creating new medications and innovations to keep their industry standing. Enhancements in drug development and innovation provide scientific insights by offering a deeper understanding of disease mechanisms, thereby hastening the discovery of new treatments. For example, in November 2022, Gilead Sciences Inc., an American biopharmaceutical firm, reported that the FDA had given approval for the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. This is to be used as a daily treatment for chronic hepatitis B virus (HBV) infection in children aged 12 years and above who have compensated liver disease. Vemlidy's approval in pediatric patients was backed by the results of a 24-week Phase 2 clinical trial.
Who Are the Key Players In The Viral Hepatitis Market?
Major companies operating in the viral hepatitis market are:
• Pfizer Inc.
• Johnson & Johnson Co
• F Hoffmann-La Roche AG
• Merck & Co.
• AbbVie Inc.
• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb
• Astra Zeneca Pharmaceuticals LP
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Co. Ltd.
• Hetero Drugs Ltd.
• Eisai Co. Ltd.
• Boehringer Ingelheim Group
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Dr. Reddy's Laboratories
• Zydus Lifescience Ltd.
• Glenmark Pharmaceuticals Ltd.
• Cipla Ltd.
• Torrent Pharmaceuticals Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Wockhardt Ltd.
What Is The Most Dominant Region In The Viral Hepatitis Market?
North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
